Boundless Bio, Inc. Common Stock (BOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.20 Million) by net assets ($110.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Boundless Bio, Inc. Common Stock (BOLD) balance sheet quality index to measure how much of total assets are equity-financed.
Boundless Bio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Boundless Bio, Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Boundless Bio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yung Zip Chemical Ind Co Ltd
TWO:4102
|
-0.018x |
|
Censof Holdings Bhd
KLSE:5195
|
0.051x |
|
Grande Group Limited Class A Ordinary Shares
NASDAQ:GRAN
|
0.028x |
|
Verena Multi Finance Tbk
JK:VRNA
|
0.085x |
|
Pamapol S.A.
WAR:PMP
|
-0.041x |
|
FASOO.COM Co Ltd
KQ:150900
|
0.045x |
|
SCGM Bhd
KLSE:7247
|
-0.031x |
|
Trend Gayrimenkul Yatirim Ortakligi AS
IS:TDGYO
|
0.222x |
Annual Cash Flow Conversion Efficiency for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of Boundless Bio, Inc. Common Stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Boundless Bio, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $150.64 Million | $-60.84 Million | -0.404x | -209.54% |
| 2023-12-31 | $-127.08 Million | $-46.85 Million | 0.369x | -23.93% |
| 2022-12-31 | $-81.70 Million | $-39.60 Million | 0.485x | -20.38% |
| 2021-12-31 | $-38.19 Million | $-23.25 Million | 0.609x | +349.62% |
| 2018-12-31 | $442.75 Million | $-107.98 Million | -0.244x | +54.81% |
| 2017-12-31 | $156.60 Million | $-84.51 Million | -0.540x | -31.42% |
| 2016-12-31 | $119.37 Million | $-49.02 Million | -0.411x | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more